{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T21:41:19Z","timestamp":1794433279527,"version":"4.9.1"},"reference-count":18,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,1,25]]},"abstract":"<jats:title>Key Points<\/jats:title>\n                  <jats:p>TP53 expression (&gt;50% positive cells) has shorter TTF and poor OS independent of both MIPI score and Ki67 index.<\/jats:p>","DOI":"10.1182\/blood-2017-07-797019","type":"journal-article","created":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T10:47:11Z","timestamp":1512125231000},"page":"417-420","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":152,"title":["Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network"],"prefix":"10.1182","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5824-0320","authenticated-orcid":false,"given":"Sietse M.","family":"Aukema","sequence":"first","affiliation":[{"name":"Department of Pathology, Hematopathology Section and Lymph Node Registry, University of Kiel, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hoster","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University Hospital Munich, Munich, Germany;"},{"name":"Institute of Medical Information Processing, Biometry, and Epidemiology, University of Munich, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Rosenwald","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University of Wurzburg, Wurzburg, Germany;"},{"name":"Comprehensive Cancer Center Mainfranken, Wurzburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Canoni","sequence":"additional","affiliation":[{"name":"Department of Pathology, Necker Hospital, Public Assistance \u2013 Hospital of Paris, University Paris Descartes, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Delfau-Larue","sequence":"additional","affiliation":[{"name":"Department of Biological Hematology and Immunology, Public Assistance \u2013 Hospital of Paris, Henri Mondor Hospital Group, Creteil, France;"},{"name":"Mondor Institute of Biomedical Research-INSERM U955, Team 9, Henri Mondor Hospital, Creteil, France;"},{"name":"Universit\u00e9 Paris-Est, Creteil, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Rymkiewicz","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Diagnostics, Maria Sklodowska Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Thorns","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Hospital Schleswig-Holstein, Lubeck, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia","family":"Hartmann","sequence":"additional","affiliation":[{"name":"Department of Pathology, University Hospital of Frankfurt, Frankfurt, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanneke","family":"Kluin-Nelemans","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[{"name":"Department of Hematology, Necker Hospital, Public Assistance \u2013 Hospital of Paris, University Paris Descartes, Paris, France; and"},{"name":"Imagine Institute, University of Sorbonne Paris City, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, University Hospital Munich, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7208-4117","authenticated-orcid":false,"given":"Wolfram","family":"Klapper","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hematopathology Section and Lymph Node Registry, University of Kiel, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2019111909372308700_B1","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","article-title":"Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network","volume":"34","author":"Hoster","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"2019111909372308700_B2","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2019111909372308700_B3","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00428-015-1840-6","article-title":"Mantle cell lymphoma--a spectrum from indolent to aggressive disease","volume":"468","author":"Sander","year":"2016","journal-title":"Virchows Arch"},{"issue":"11","key":"2019111909372308700_B4","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3324\/haematol.2009.010264","article-title":"SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype","volume":"94","author":"Mozos","year":"2009","journal-title":"Haematologica"},{"issue":"18","key":"2019111909372308700_B5","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1182\/blood-2011-12-400580","article-title":"Prognostic role of SOX11 in a population-based cohort of mantle cell lymphoma","volume":"119","author":"Nygren","year":"2012","journal-title":"Blood"},{"issue":"2","key":"2019111909372308700_B6","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1365-2141.2008.07329.x","article-title":"The subcellular Sox11 distribution pattern identifies subsets of mantle cell lymphoma: correlation to overall survival","volume":"143","author":"Wang","year":"2008","journal-title":"Br J Haematol"},{"issue":"4","key":"2019111909372308700_B7","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/0008-5472.CAN-09-3419","article-title":"Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma","volume":"70","author":"Fern\u00e0ndez","year":"2010","journal-title":"Cancer Res"},{"issue":"1","key":"2019111909372308700_B8","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1111\/bjh.12854","article-title":"SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma--a Nordic Lymphoma Group study","volume":"166","author":"Nordstr\u00f6m","year":"2014","journal-title":"Br J Haematol"},{"issue":"8","key":"2019111909372308700_B9","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.3324\/haematol.2010.036277","article-title":"Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis","volume":"96","author":"Ondrejka","year":"2011","journal-title":"Haematologica"},{"issue":"3","key":"2019111909372308700_B10","first-page":"699","article-title":"Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphoma","volume":"36","author":"Stefancikova","year":"2010","journal-title":"Int J Oncol"},{"issue":"10044","key":"2019111909372308700_B11","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","article-title":"Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"issue":"6","key":"2019111909372308700_B12","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"2019111909372308700_B13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/PAS.0b013e3182a43996","article-title":"Assessment of SOX11 expression in routine lymphoma tissue sections: characterization of new monoclonal antibodies for diagnosis of mantle cell lymphoma","volume":"38","author":"Soldini","year":"2014","journal-title":"Am J Surg Pathol"},{"issue":"17","key":"2019111909372308700_B14","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1182\/blood-2017-04-779736","article-title":"TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy","volume":"130","author":"Eskelund","year":"2017","journal-title":"Blood"},{"issue":"8","key":"2019111909372308700_B15","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1182\/blood.V87.8.3351.bloodjournal8783351","article-title":"p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas","volume":"87","author":"Hernandez","year":"1996","journal-title":"Blood"},{"issue":"10","key":"2019111909372308700_B16","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1182\/blood.V87.10.4302.bloodjournal87104302","article-title":"p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis","volume":"87","author":"Greiner","year":"1996","journal-title":"Blood"},{"issue":"5","key":"2019111909372308700_B17","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1182\/blood-2015-02-628792","article-title":"High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma","volume":"126","author":"Delfau-Larue","year":"2015","journal-title":"Blood"},{"issue":"15","key":"2019111909372308700_B18","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1200\/JCO.2016.70.7901","article-title":"New molecular assay for the proliferation signature in mantle cell lymphoma applicable to formalin-fixed paraffin-embedded biopsies","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/131\/4\/417\/1465553\/blood797019.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/131\/4\/417\/1465553\/blood797019.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T13:11:24Z","timestamp":1574169084000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/131\/4\/417\/38488\/Expression-of-TP53-is-associated-with-the-outcome"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,25]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,1,25]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-07-797019","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732219467.793548357","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,25]]}}}